三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
CD3/DLL3主要相关药物临床进展(截至2025H1)
CD3/DLL3主要相关药物临床进展(截至2025H1)
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:113KB
图片尺寸:2280*499
同报告图片
/
4
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
所属报告:
泽璟制药-公司研究报告-创新进入收获期ZG006及ZG005均有望成为BIC-250714(37页).pdf
打包全文图表
相关数据
安进的CD3/DLL3双抗Tarlatamab于2024年5月获FDA加速批准上市
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
收藏
行业数据
2025-05-13
原图定位
查看详情
安进的CD3/DLL3双抗Tarlatamab于2024年5月获FDA加速批准上市
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
收藏
行业数据
2024-12-31
原图定位
查看详情
全球CD3/DLL3双抗或多抗药物研发格局
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
收藏
其它
2024-07-12
原图定位
查看详情
全球DLL3/CD3抗体进度(部分产品梳理)
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
收藏
其它
2024-07-10
原图定位
查看详情
全球CD3/DLL3双抗或多抗物发格局
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
收藏
其它
2024-07-04
原图定位
查看详情
现有CD3/DLL3双抗临床数据对比分析
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
收藏
其它
2024-07-04
原图定位
查看详情
不同CD3/DLL3双抗产品设计对比
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
收藏
其它
2024-07-04
原图定位
查看详情
Tarlatama具有全球首创的CD3/DLL3抗肿瘤作用机制
fCDnu4bog57nsbvlnosgICB8IOeJueW+gSAgICAgICAgICAgICAgICAgICAgICAgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18CnwgVGFybGF0YW1hYiB8IENEM+e7k+WQiOWfn+OAgURMTDPnu5PlkIjln5/jgIHml6DmlYjlupRGY+WfnyB8CnwgVOe7huiDniAgICAgIHwgQ0Qz44CBVOe7huiDnuaJqeWiniAgICAgICAgICAgICB8CnwgU0NMQ+e7huiDniAgIHwgRExMM+OAgeiCv+eYpOe7huiDnuWHi+S6oSAgICAgICAgIHwKCgrotYTmlpnmnaXmupDvvJrlronov5vlhazlj7hFU01P5bm05Lya5ryU56S65p2Q5paZ
收藏
其它
2024-02-27
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
DLL3 全球进展(统计截至 2025H1):安进的 CD3/DLL3 双抗塔拉妥单抗(Tarlatamab)针对末线 SCLC 患者临床试验的疗效突出,使得后线患者 mOS 由 8 个月提高至 14.3 个月,因而于 2024 年 5 月获得美国 FDA 加速批准上市;紧随其后为勃林格殷格翰/中国生物制药的 CD3/DLL3 双抗(国内外均为Ⅱ期)、公司的 CD3/DLL3/DLL3 三抗(国内Ⅱ期、国外Ⅰ期)。除了双抗/三抗之外,再鼎医药以及百利天恒的 DLL3 ADC、传奇生物的 DLL3 CAR-T 等均已步入临床阶段。
行业数据
原图定位
当前图表所属:
泽璟制药-公司研究报告-创新进入收获期ZG006及ZG005均有望成为BIC-250714(37页).pdf
自免疾病具备广阔的临床应用和市场潜力
PD-1/TIGIT药物主要进展(截至2025H1)
CD3/DLL3主要相关药物临床进展(截至2025H1)
小细胞肺癌免疫治疗专家共识(2025版)要点
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》